Outcome Measures in Interventional Trials for Prevention or Treatment of Venous Thrombosis in the Pediatric Population

 

 Buy Article Permissions and Reprints

ABSTRACT

Determining clinically relevant outcomes are one of the key issues in the design of clinical trials. Recently, a working group from the Perinatal and Pediatric Subcommittee of the Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis published a position article defining outcomes in interventional trials for prevention and treatment of deep vein thrombosis (DVT) in children. For these studies the primary efficacy outcomes are DVT and the primary safety outcomes are bleeding. The exact definitions for these outcomes are included in this review article. This article expands on these recommendations by summarizing and reviewing the current literature in pediatric anticoagulation studies; discussing the relationship of choice of outcomes to specific clinical trial design; providing a more detailed discussion on the rationale for the defined outcomes in pediatric anticoagulation trials, as well as a detailed examination of secondary and tertiary outcomes. With a growing interest in multicenter, multinational pediatric anticoagulation clinical trials, establishment of standardized outcome measures that are applied uniformly over all studies is critically important. Agreement from the international academic community on these outcomes is an important step in assuring well-designed clinical trials, which are implemented to optimize the prevention and treatment of DVT in children.

REFERENCES

• 1 Massicotte P, Julian J A, Gent M PROTEKT Study Group et al. An open-label randomized controlled trial of low molecular weight heparin for the prevention of central venous line-related thrombotic complications in children: the PROTEKT trial.  Thromb Res. 2003;  109 (2-3) 101-108
  Google Scholar
• 2 Massicotte P, Julian J A, Gent M REVIVE Study Group et al. An open-label randomized controlled trial of low molecular weight heparin compared to heparin and coumadin for the treatment of venous thromboembolic events in children: the REVIVE trial.  Thromb Res. 2003;  109 (2-3) 85-92
  Google Scholar
• 3 Mitchell L, Andrew M, Hanna K et al.. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l-asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study.  Thromb Haemost. 2003;  90 (2) 235-244
  Google Scholar
• 4 Alton G Y, Robertson C M, Sauve R Western Canadian Complex Pediatric Therapies Project Follow-Up Group et al. Early childhood health, growth, and neurodevelopmental outcomes after complete repair of total anomalous pulmonary venous connection at 6 weeks or younger.  J Thorac Cardiovasc Surg. 2007;  133 (4) 905-911
  Google Scholar
• 5 Kuhle S, Massicotte P, Dinyari M et al.. Dose-finding and pharmacokinetics of therapeutic doses of tinzaparin in pediatric patients with thromboembolic events.  Thromb Haemost. 2005;  94 (6) 1164-1171
  Google Scholar
• 6 Ruud E, Holmstrøm H, De Lange C, Hogstad E M, Wesenberg F. Low-dose warfarin for the prevention of central line-associated thromboses in children with malignancies—a randomized, controlled study.  Acta Paediatr. 2006;  95 (9) 1053-1059
  Google Scholar
• 7 Schroeder A R, Axelrod D M, Silverman N H, Rubesova E, Merkel E, Roth S J. A continuous heparin infusion does not prevent catheter-related thrombosis in infants after cardiac surgery.  Pediatr Crit Care Med. 2010;  11 (4) 489-495
  Google Scholar
• 8 Young G, Tarantino M D, Wohrley J, Weber L C, Belvedere M, Nugent D J. Pilot dose-finding and safety study of bivalirudin in infants <6 months of age with thrombosis.  J Thromb Haemost. 2007;  5 (8) 1654-1659
  Google Scholar
• 9 Mitchell L G, Goldenberg N A, Male C, Kenet G, Monagle P, Nowak-Göttl U. on behalf of the Perinatal and Paediatric Haemostasis Subcommittee of the SSC of the ISTH . Definition of clinical efficacy and safety outcomes for clinical trials in deep venous thrombosis and pulmonary embolism in children.  J Thromb Haemost. 2011;  9 (9) 1856-1858
  Google Scholar
• 10 Lensing A W, Hirsh J, Buller H R. Diagnosing venous thrombosis. In: Venous Thrombosis. Philadelphia: J.B. Lippincott; 1994: 1297-1321
  Google Scholar
• 11 Molloy W, English J, O'Dwyer R, O'Connell J. Clinical findings in the diagnosis of proximal deep vein thrombosis.  Ir Med J. 1982;  75 (4) 119-120
  Google Scholar
• 12 Mitchell L G, Andrew M, Hanna K Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase Group (PARKAA) et al. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase: results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) Study.  Cancer. 2003;  97 (2) 508-516
  Google Scholar
• 13 Lensing A W, Büller H R, Prandoni P et al.. Contrast venography, the gold standard for the diagnosis of deep-vein thrombosis: improvement in observer agreement.  Thromb Haemost. 1992;  67 (1) 8-12
  Google Scholar
• 14 Prandoni P, Polistena P, Bernardi E et al.. Upper-extremity deep vein thrombosis. Risk factors, diagnosis, and complications.  Arch Intern Med. 1997;  157 (1) 57-62
  Google Scholar
• 15 Lensing A W, Prandoni P, Brandjes D et al.. Detection of deep-vein thrombosis by real-time B-mode ultrasonography.  N Engl J Med. 1989;  320 (6) 342-345
  Google Scholar
• 16 Baarslag H J, van Beek E J, Koopman M M, Reekers J A. Prospective study of color duplex ultrasonography compared with contrast venography in patients suspected of having deep venous thrombosis of the upper extremities.  Ann Intern Med. 2002;  136 (12) 865-872
  Google Scholar
• 17 Male C, Chait P, Ginsberg J S et al.. Comparison of venography and ultrasound for the diagnosis of asymptomatic deep vein thrombosis in the upper body in children: results of the PARKAA study. Prophylactic Antithrombin Replacement in Kids with ALL treated with Asparaginase.  Thromb Haemost. 2002;  87 (4) 593-598
  Google Scholar
• 18 Baarslag H J, Koopman M M, Reekers J A, van Beek E J. Diagnosis and management of deep vein thrombosis of the upper extremity: a review.  Eur Radiol. 2004;  14 (7) 1263-1274
  Google Scholar
• 19 Kuhle S, Spavor M, Massicotte P et al.. Prevalence of post-thrombotic syndrome following asymptomatic thrombosis in survivors of acute lymphoblastic leukemia.  J Thromb Haemost. 2008;  6 (4) 589-594
  Google Scholar
• 20 Kuhle S, Koloshuk B, Marzinotto V et al.. A cross-sectional study evaluating post-thrombotic syndrome in children.  Thromb Res. 2003;  111 (4-5) 227-233
  Google Scholar
• 21 van Ommen C H, Ottenkamp J, Lam J et al.. The risk of postthrombotic syndrome in children with congenital heart disease.  J Pediatr. 2002;  141 (4) 582-586
  Google Scholar
• 22 Goldenberg N A, Knapp-Clevenger R, Manco-Johnson M J. Mountain States Regional Thrombophilia Group . Elevated plasma factor VIII and D-dimer levels as predictors of poor outcomes of thrombosis in children.  N Engl J Med. 2004;  351 (11) 1081-1088
  Google Scholar
• 23 Goldenberg N A, Durham J D, Knapp-Clevenger R, Manco-Johnson M J. A thrombolytic regimen for high-risk deep venous thrombosis may substantially reduce the risk of postthrombotic syndrome in children.  Blood. 2007;  110 (1) 45-53
  Google Scholar
• 24 Kreuz W, Stoll M, Junker R et al.. Familial elevated factor VIII in children with symptomatic venous thrombosis and post-thrombotic syndrome: results of a multicenter study.  Arterioscler Thromb Vasc Biol. 2006;  26 (8) 1901-1906
  Google Scholar
• 25 Schobess R, Düring C, Bidlingmaier C, Heinecke A, Merkel N, Nowak-Göttl U. Long-term safety and efficacy data on childhood venous thrombosis treated with a low molecular weight heparin: an open-label pilot study of once-daily versus twice-daily enoxaparin administration.  Haematologica. 2006;  91 (12) 1701-1704
  Google Scholar
• 26 Sharathkumar A A, Pipe S W. Post-thrombotic syndrome in children: a single center experience.  J Pediatr Hematol Oncol. 2008;  30 (4) 261-266
  Google Scholar
• 27 van Ommen C H, Heijboer H, van den Dool E J, Hutten B A, Peters M. Pediatric venous thromboembolic disease in one single center: congenital prothrombotic disorders and the clinical outcome.  J Thromb Haemost. 2003;  1 (12) 2516-2522
  Google Scholar
• 28 Galanis T, Thomson L, Palladino M, Merli G J. New oral anticoagulants.  J Thromb Thrombolysis. 2011;  31 (3) 310-320
  Google Scholar
• 29 Nowak-Göttl U, Dietrich K, Schaffranek D et al.. In pediatric patients, age has more impact on dosing of vitamin K antagonists than VKORC1 or CYP2C9 genotypes.  Blood. 2010;  116 (26) 6101-6105
  Google Scholar
• 30 Streif W, Andrew M, Marzinotto V et al.. Analysis of warfarin therapy in pediatric patients: A prospective cohort study of 319 patients.  Blood. 1999;  94 (9) 3007-3014
  Google Scholar
• 31 Anton N, Cox P N, Massicotte M P et al.. Heparin-bonded central venous catheters do not reduce thrombosis in infants with congenital heart disease: a blinded randomized, controlled trial.  Pediatrics. 2009;  123 (3) e453-e458
  Google Scholar

Lesley G. MitchellM.Sc. 

University of Alberta, Dentistry Pharmacy Centre

11304-89 Avenue, Edmonton, AB T6G 2C7, Canada

Email: Lesley.Mitchell@albertahealthservices.ca